OTCMKTS:BGMD

BG Medicine Stock Forecast, Price & News

$0.08
0.00 (0.00 %)
(As of 06/11/2021 10:02 AM ET)
Add
Compare
Today's Range
$0.08
$0.08
50-Day Range
$0.04
$0.10
52-Week Range
$0.01
$0.26
Volume300 shs
Average Volume25,419 shs
Market Capitalization$922,677.00
P/E RatioN/A
Dividend YieldN/A
Beta0.83
30 days | 90 days | 365 days | Advanced Chart
Receive BGMD News and Ratings via Email

Sign-up to receive the latest news and ratings for BG Medicine and its competitors with MarketBeat's FREE daily newsletter.


BG Medicine logo

About BG Medicine

BG Medicine, Inc. engages in the development and commercialization of diagnostic products used to guide the patients suffering from heart failure and related disorders in the United States. The company offers BGM Galectin-3 Test, an in vitro diagnostic device that measures galectin-3 in serum or plasma by enzyme linked immunosorbent assay on a microtiter plate platform; and CardioSCORE Test, a multi-analyte biomarker-based blood test used for the assessment of near-term risk of atherothrombotic cardiovascular events, such as heart attack and ischemic stroke. It has license, development, and commercialization agreements with Abbott Laboratories, bioMérieux SA, Siemens Healthcare Diagnostics Inc., and Alere Inc. for the automated instrument versions of galectin-3 test; and a strategic collaboration with Abbott Laboratories to develop and commercialize galectin-3 assay kits, and related control kits and calibrators. The company was formerly known as Beyond Genomics, Inc. and changed its name to BG Medicine, Inc. in October 2004. BG Medicine, Inc. was founded in 2000 and is headquartered in Waltham, Massachusetts.

Headlines

See More Headlines

Industry, Sector and Symbol

Sales & Book Value

Profitability

Debt

Price-To-Earnings

Miscellaneous


MarketRank

Overall MarketRank

0.46 out of 5 stars

Medical Sector

1721st out of 2,099 stocks

Diagnostic Substances Industry

31st out of 35 stocks

Analyst Opinion: 0.0Community Rank: 2.3Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles











BG Medicine (OTCMKTS:BGMD) Frequently Asked Questions

What stocks does MarketBeat like better than BG Medicine?

Wall Street analysts have given BG Medicine a "N/A" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but BG Medicine wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting BG Medicine?

BG Medicine saw a increase in short interest in the month of May. As of May 28th, there was short interest totaling 3,200 shares, an increase of 1,500.0% from the May 13th total of 200 shares. Based on an average trading volume of 101,600 shares, the short-interest ratio is presently 0.0 days.
View BG Medicine's Short Interest
.

How were BG Medicine's earnings last quarter?

BG Medicine, Inc. (OTCMKTS:BGMD) announced its quarterly earnings data on Tuesday, November, 17th. The medical research company reported ($0.27) earnings per share (EPS) for the quarter. The medical research company had revenue of $334 million for the quarter, compared to analysts' expectations of $695 million.
View BG Medicine's earnings history
.

How has BG Medicine's stock price been impacted by COVID-19 (Coronavirus)?

BG Medicine's stock was trading at $0.0151 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, BGMD shares have increased by 449.0% and is now trading at $0.0829.
View which stocks have been most impacted by COVID-19
.

Who are BG Medicine's key executives?

BG Medicine's management team includes the following people:
  • Dr. Paul R. Sohmer, CEO, Pres & Director (Age 72, Pay $429.17k)
  • Mr. Stephen P. Hall, CFO, Exec. VP & Treasurer (Age 70, Pay $351.03k)
  • Dr. Aram Adourian, Chief Scientific Officer (Age 51)

Who are some of BG Medicine's key competitors?

What other stocks do shareholders of BG Medicine own?

Based on aggregate information from My MarketBeat watchlists, some companies that other BG Medicine investors own include Aeterna Zentaris (AEZS), Glu Mobile (GLUU), (MHRCQ) (MHRCQ), ARCA biopharma (ABIO), Athersys (ATHX), Catalyst Pharmaceuticals (CPRX), InterCloud Systems (ICLD), Inovio Pharmaceuticals (INO), Inpixon (INPX) and LightPath Technologies (LPTH).

What is BG Medicine's stock symbol?

BG Medicine trades on the OTCMKTS under the ticker symbol "BGMD."

How do I buy shares of BG Medicine?

Shares of BGMD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is BG Medicine's stock price today?

One share of BGMD stock can currently be purchased for approximately $0.08.

How much money does BG Medicine make?

BG Medicine has a market capitalization of $922,677.00.

How many employees does BG Medicine have?

BG Medicine employs 5 workers across the globe.

What is BG Medicine's official website?

The official website for BG Medicine is www.bg-medicine.com.

Where are BG Medicine's headquarters?

BG Medicine is headquartered at 303 Wyman Street Suite 300, Waltham MA, 02451.

How can I contact BG Medicine?

BG Medicine's mailing address is 303 Wyman Street Suite 300, Waltham MA, 02451. The medical research company can be reached via phone at 781-890-1199 or via email at [email protected]


This page was last updated on 6/14/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.